这些克隆具有STRACK:追踪对白血病突变的反应
1Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Institute of Regenerative Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center for Advancement of Blood Cancer Therapies, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Cell stem cell
|April 4, 2025
概括
研究人员使用遗传条形码和姐妹细胞分析来研究突变如何影响造血干细胞 (HSC). 这揭示了细胞行为的内在差异,这些差异影响了白血病的发展.
科学领域:
- 血液学 血液学 血液学
- 干细胞生物学 干细胞生物学
- 癌症研究 癌症研究
背景情况:
- 造血干细胞 (HSC) 对于血液形成至关重要.
- 白血病源于高血糖细胞的突变,但它们的内在异质性使得理解疾病发病变化变得复杂.
- 之前的研究缺乏方法来追踪个体细胞在获得突变后的行为.
研究的目的:
- 研究白血病驱动突变对单个小鼠造血干细胞 (HSC) 行为的影响.
- 了解细胞内在异质性如何影响HSC在获得突变时的命运决定.
- 在早期白血病发育的背景下,开发一种捕获和分析克隆细胞行为的方法.
主要方法:
- 使用遗传条形码来标记单个HSC及其后代.
- 使用ex vivo扩张培养和观察HSC克隆.
- 进行姐妹细胞分析,以比较具有和没有诱导白血病驱动突变的姐妹细胞的命运.
主要成果:
- 在具有相同突变的HSC中,在克隆细胞行为中显示出显著的异质性.
- 确定了特定的行为差异,使某些HSC克隆容易发生白血病转变.
- 展示了细胞内在特性,而不仅仅是突变,如何决定白血病的进展.
结论:
- 内在的细胞异质性在白血病的发病和进展中起着关键作用.
- 开发的方法允许对干细胞突变中的克隆动态进行详细分析.
- 了解HSC异质性是开发针对白血病的向治疗的关键.
相关概念视频
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cells of the Adaptive Immune Response
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
T Cell Activation and Clonal Selection
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...


